VCM
AXSM icon

Voleon Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Voleon Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25M Buy
147,867
+37,688
+34% +$6.51M 0.54% 32
2025
Q4 		$20.1M Buy
110,179
+93,445
+558% +$13M 0.43% 41
2025
Q3 		$2.03M Buy
+16,734
New +$1.88M 0.05% 308

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voleon Capital Management's AXSM Position: Q1 2026 in Review

Voleon Capital Management increased its Axsome Therapeutics (AXSM) stake by 34% in Q1 2026, buying an estimated $6.51M and bringing the position to 147,867 shares worth $25M. The position accounts for 0.54% of the portfolio, ranked #32.

Voleon Capital Management first reported a position in AXSM in Q3 2025 and has held it in 3 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Voleon Capital Management held 147,867 shares of Axsome Therapeutics worth $25M as of Q1 2026.
  • Voleon Capital Management bought 37,688 Axsome Therapeutics shares in Q1 2026, an estimated $6.51M.
  • Axsome Therapeutics made up 0.54% of Voleon Capital Management's portfolio in Q1 2026, its #32 holding.
  • Voleon Capital Management first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.